Hereditary Hemorrhagic Telangiectasia | NEJM
Images in Clinical Medicine from The New England Journal of Medicine — Hereditary Hemorrhagic Telangiectasia
Related Articles
Andexanet alfa: trials just leave us with more questions
ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with…
Andexanet alfa: trials just leave us with more questions
ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with…
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended…
Publicly funded US research will have to be published without delay under new policy
Research funded by the US National Institutes of Health (NIH) will have to be made publicly available without a period of delay,1 under the agency’s…
FDA approves drug to prevent or reduce the frequency of bleeding episodes for patients with hemophilia A with inhibitors or hemophilia B with inhibitors
Action The U.S. Food and Drug Administration has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce the frequency of bleeding
Hematologists Should Consider Sitosterolemia in Patients with Hemolytic Anemia, Thrombocytopenia, and High Cholesterol | ASH Clinical News | American Society of Hematology
Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. Population: Roughly 1 in 200,000 people across ethnicities; may present…
Adeno-associated virus–based gene therapy for hemophilia A and B: a systematic review and meta-analysis
Abstract. Adeno-associated virus (AAV)–based gene therapy is an emerging treatment for hemophilia A (HA) and hemophilia B (HB). In this systematic review a
Sitosterolemia with Orbital Xanthogranulomas | NEJM
A 50-year-old woman presented with a 5-year history of xanthogranulomas under her eyes. Laboratory studies were notable for thrombocytopenia and very high levels of low-density…
Job Advert
Skip to main content We’ ve put some small files called cookies on your device to help us make improvements to our site. To improve…
My gene therapy journey – Medical Independent
Mr Brian O’Mahony, Chief Executive, Irish Haemophilia Society, recounts his experience of participating in a gene therapy…